Cardiovascular risk evaluations using a risk parameter that includes an HDL and inflammatory biomarker interaction parameter
AssigneeLipoScience, Inc.
InventorsJames D. Otvos, Irina Y. Shalaurova
Life of this patent
Estimating the term…
Abstract
Methods, systems and circuits evaluate a subject's CVD risk using a risk parameter that includes at least one HDL and inflammatory biomarker interaction parameter. The inflammatory biomarker may optionally comprise NMR derived measurements of GlycA from at least one biosample of the subject. The risk parameter may be gender-specific.
Claims30
A method of determining a risk parameter for cardiovascular disease (CVD) or events, comprising:
- providing a Nuclear Magnetic Resonance (NMR) spectrum of an in vitro biosample comprising blood, plasma, or serum from a subject;
- obtaining measurements of HDL particles and inflammatory biomarker GlycA in the biosample;
- determining NMR-derived concentrations for an HDL particle size subclass and GlycA, based on the measurements;
- programmatically calculating a risk parameter value ((HxI)CVD) of the subject using the NMR-derived concentrations for the HDL particle size subclass and GlycA;
- and
- determining the subject's risk of having and/or developing CVD based, at least in part, on the (HxI)CVD risk parameter value.
A system for determining a risk parameter for cardiovascular disease or events, comprising:
- a Nuclear Magnetic Resonance (NMR) spectrometer configured to acquire an NMR signal of an in vitro biosample comprising blood, plasma, or serum from a subject;
- and
- a processor in communication with the NMR spectrometer, the processor configured to:
- determine NMR-derived concentrations from the NMR signal for an HDL particle size subclass and inflammatory biomarker GlycA;
- and
- programmatically calculate a risk parameter ((HxI)CVD) of the subject using the concentrations for the HDL particle size subclass and inflammatory biomarker GlycA.
A computer program product for determining a risk parameter for cardiovascular disease or events, the computer program product comprising:
- a non-transitory computer readable storage medium having computer readable program code embodied in the medium, the computer-readable program code comprising:
- computer readable program code that obtains NMR-derived measurements for at least eight subclasses of HDL-P in a blood, plasma, or serum sample and inflammatory biomarker GlycA;
- computer readable program code that determines concentrations of HDL particle size subclasses and/or inflammatory biomarker GlycA using the NMR-derived measurements;
- and
- computer readable program code that calculates a risk parameter ((HxI)CVD) comprising at least one interaction parameter.
Dependencies are inferred from the claim text.